Anifrolumab Benefits Seen in Second Lupus RCT Analysis Anifrolumab Benefits Seen in Second Lupus RCT Analysis

The monoclonal anifrolumab improved BICLA responses, reduced use of prednisone, and improved skin disease in patients with SLE, particularly those with high type 1 interferon gene signatures.Medscape Medical News

Source: Medscape Medical News Headlines - December 23, 2019 Category: Consumer Health News Tags: Rheumatology News Source Type: news